title: Haemophagocytic lymphohistiocytosis: from diagnostic challenges to predictive possibilities.
authors.affiliation: Department of Clinical Medicine and Rheumatology, Campus Bio-Medico University Hospital and School of Medicine, Rome, Italy Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Soriano
authors.affiliation: Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel shoenfel@post.tau.ac.il.
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D016572:Cyclosporine / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D003907:Dexamethasone / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D010951:Plasma Exchange / Q000379:methods; D011237:Predictive Value of Tests; D059005:Topoisomerase II Inhibitors / Q000627:therapeutic use
chemical_list: D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D059005:Topoisomerase II Inhibitors; D005047:Etoposide; D003907:Dexamethasone; D016572:Cyclosporine